As reported by NHS England, a pioneering capsule sponge test, trialled by the NHS, has significantly reduced the need for invasive endoscopy in diagnosing Barrett’s oesophagus, potentially preventing oesophageal cancer and easing patient discomfort
The NHS pilot has tested over 8,500 patients with the capsule sponge test. Evaluation of a cohort of patients showed almost eight out of 10 patients, who completed a test were discharged without the need for further testing, freeing up endoscopy capacity for higher risk patients and those referred for urgent tests for oesophageal cancer.
The test involves patients swallowing a small capsule-shaped device which contains a tiny sponge that collects cell samples for analysis before being extracted via a string attached to the sponge.
Barrett’s oesophagus – a condition affecting the food pipe which can go on to cause oesophageal cancer in some patients – is usually diagnosed or ruled out via endoscopy (a camera test of the food pipe) following a GP referral to a gastroenterologist or other specialist practitioner who can carry out the procedure.
The sponge-on-a-string test being trialled by the NHS can instead be carried out quickly in a short appointment, without the need for sedation.
In a survey of over 350 patients who had the capsule sponge test, patients often said they would recommend the test to a friend or family member, and 94% of patients reported experiencing only mild or no pain at all.
Amanda Pritchard, NHS chief executive, said: “Thousands of people have now benefitted from this incredibly efficient test on the NHS – while the sponge on a string is small in size, it can make a big difference for patients – they can conveniently fit the test into their day and it can often replace the need for an endoscopy while also helping to reduce waiting lists by freeing up staff and resources.
“The NHS is always striving to adopt the latest innovations and new ways of working that help improve patient experience and increase efficiency – this simple sponge on a string test is just one example of many pioneering tools we’ve trialled in recent years to help diagnose and treat people sooner.”
The NHS began piloting the test during the pandemic when there was increased pressure on services and a growing backlog for endoscopy.
Gastro-oesophageal reflux, also known as acid reflux, is a relatively common condition, affecting around one to two in every ten people to some degree, and some of these people may already have or will develop Barrett’s oesophagus, which is a precursor to oesophageal cancer.
There are around 9,300 new oesophageal cancer cases in the UK every year. The key to saving lives is to detect it an earlier stage of Barrett’s oesophagus before it becomes cancerous.
The pilot was launched at 30 hospital sites across 17 areas in England including Manchester, Plymouth, London, Kent and Cumbria.
Evaluation of the NHS pilot showed that using the capsule sponge was highly cost effective compared to using endoscopy-only for diagnosing patients – saving around £400 per patient.
Patients with positive results from the capsule sponge test who were referred on for an endoscopy had the highest prevalence of Barrett’s oesophagus at 27.2%, compared to zero patients with negative results who completed an endoscopy.
One of the first pilot sites at East and North Hertfordshire NHS Trust has now performed around 1,400 capsule sponge tests – offering to both patients with reflux symptoms via a new consultant led, nurse run early diagnosis service, as well as to patients who are on an existing Barrett’s surveillance programme.
In the first 1000 patients, the capsule test identified Barrett’s in 6% patients with reflux and found two new cancers and three patients with dysplasia who may have had a longer time to diagnosis otherwise. While 72% reflux patients were discharged back to their GP without the need for an endoscopy.
As of January, 368 patients have had a positive test result of whom about half have confirmed Barrett’s oesophagus.
Be the first to comment